Table 3.
ALK TKIs in the clinic
| ALK inhibitors (reference) | ROS1 activity | Status | NCT identifier |
|---|---|---|---|
| Crizotinib [68, 69, 76] | Yes | Approved for ALK-positive NSCLC; investigational for ROS1 | NCT00585195 |
| Ceritinib (LDK378) [77] | Yes | Phase II/III | NCT01828099, NCT01828112 |
| Alectinib (CH5424802) [78, 79] | No | Phase I/II | NCT01588028 |
| AP26113 [80] | Yes | Phase I/II | NCT01449461 |
| ASP3026 [81] | Yes | Phase I | NCT01284192 |
Modified from Brahmer et al. [82]